Vanderbilt Eye Institute

Vanderbilt Eye Institute is one of a handful of places in Nashville that can fit patients for lenses designed to accommodate any degree of corneal steepness or irregularity.

A multi-institutional study found that low-dose atropine eyedrops, commonly used in a higher dose to treat lazy eye, was no better than a placebo at slowing myopia (nearsightedness) progression and elongation of the eye among children treated for two years.

Paul Sternberg Jr., MD, was celebrated last week at a retirement ceremony honoring his 20 years of service to Vanderbilt University Medical Center as chair of the Department of Ophthalmology and Visual Sciences and founding director of the Vanderbilt Eye Institute.

David Wallace, MD, MPH, has been named as the new chair of Ophthalmology and Visual Sciences and director of the Vanderbilt Eye Institute.

Vanderbilt's Project PAVE has received funding from the Tennessee Department of Intellectual and Developmental Disabilities to continue the program that has provided low-vision evaluations for more than 2,150 school-age children in Tennessee since 1993.

A metalloprotease enzyme plays an important role in retinal ganglion cell development, Vanderbilt researchers discovered; studying it and other family members may lead to the identification of novel targets for treating glaucoma.

A $10 million gift from the International Retinal Research Foundation will establish a center dedicated to retinal vision research at the Vanderbilt Eye Institute and a directorship to support a physician-scientist leader in the Department of Ophthalmology and Visual Sciences.